within Pharmacolibrary.Drugs.ATC.S;

model S01CC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.00015 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 5e-06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed combination ophthalmic drug containing diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), and antimicrobial agents for the prevention and treatment of post-surgical inflammation and potential infection of the eye. Formulated for topical ocular use. While diclofenac is widely approved and used as an NSAID, this specific fixed combination is not widely used or available in all regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for diclofenac in ocular (ophthalmic) application in adult patients, as no explicit published population PK model for the fixed combination exists.</p><h4>References</h4><ol><li><p>Sun, R, et al., &amp; Zhang, Y (2024). An adaptive drug-releasing contact lens for personalized treatment of ocular infections and injuries. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 369 114–127. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2024.03.040&quot;>10.1016/j.jconrel.2024.03.040</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38521167/&quot;>https://pubmed.ncbi.nlm.nih.gov/38521167</a></p></li><li><p>Krustev, SZ, et al., &amp; Haritova, AM (2014). Effect of diclofenac on ocular levels of ciprofloxacin and lomefloxacin in rabbits with endophthalmitis. <i>Drug development and industrial pharmacy</i> 40(11) 1459–1462. DOI:<a href=&quot;https://doi.org/10.3109/03639045.2013.828225&quot;>10.3109/03639045.2013.828225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23937580/&quot;>https://pubmed.ncbi.nlm.nih.gov/23937580</a></p></li><li><p>Juretić, M, et al., &amp; Pepić, I (2018). Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 120 133–141. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2018.04.032&quot;>10.1016/j.ejps.2018.04.032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29702232/&quot;>https://pubmed.ncbi.nlm.nih.gov/29702232</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01CC01;
